Nuclear factor kappa B may increase insight into the management of neuroinflammation and excitotoxicity in autism

Bibliography

• Villagonzalo KA, Dodd S, Dean O, Oxidative pathways as a drug target for the treatment of autism. Expert Opin Ther Targets 2010;15(12):1301-10
   Google Scholar
• Malik M, Sheikh AM, Wen G, Expression of inflammatory cytokines, Bcl2 and cathepsin D are altered in lymphoblasts of autistic subjects. Immunobiology 2011;216(1-2):80-5
   PubMedGoogle Scholar
• Sheikh AM, Li X, Wen G, Cathepsin D and apoptosis related proteins are elevated in the brain of autistic subjects. Neuroscience 2010;165(2):363-70
   PubMedGoogle Scholar
• Li X, Chauhan A, Sheikh AM, Elevated immune response in the brain of autistic patients. J Neuroimmunol 2009;207(1-2):111-16
   PubMedGoogle Scholar
• Cohly HH, Panja A. Immunological findings in autism. Int Rev Neurobiol 2005;71:317-41
   PubMed Web of Science ®Google Scholar
• Jyonouchi H, Sun S, Le H. Proinflammatory and regulatory cytokine production associated with innate and adaptive immune responses in children with autism spectrum disorders and developmental regression. J Neuroimmunol 2001;120(1-2):170-9
   PubMedGoogle Scholar
• Shinohe A, Hashimoto K, Nakamura K, Increased serum levels of glutamate in adult patients with autism. Prog Neuropsychopharmacol Biol Psychiatry 2006;30(8):1472-7
   PubMedGoogle Scholar
• Blaylock RL. A possible central mechanism in autism spectrum disorders, part 1. Altern Ther Health Med 2008;14(6):46-53
   PubMedGoogle Scholar
• Ghanizadeh A. May lovastatin target both autism and epilepsy? A novel hypothesized treatment. Epilepsy Behav 2011;20(2):422
   PubMedGoogle Scholar
• Ghanizadeh A. Methionine sulfoximine may improve inflammation in autism, a novel hypothesized treatment for autism. Arch Med Res 2010;41(8):651-2
   PubMedGoogle Scholar
• Ghanizadeh A. c-Kit+ cells transplantation as a new treatment for autism, a novel hypothesis with important research and clinical implication. J Autism Dev Disord 2011. [Epub ahead of print]
   Google Scholar
• Ghanizadeh A. Targeting neurotensin as a potential novel approach for the treatment of autism. J Neuroinflammation 2010;7:58
   PubMedGoogle Scholar
• Ghezzi P, Mennini T. Tumor necrosis factor and motoneuronal degeneration: an open problem. Neuroimmunomodulation 2001;9(4):178-82
   PubMedGoogle Scholar
• Kaltschmidt B, Widera D, Kaltschmidt C. Signaling via NF-kappaB in the nervous system. Biochim Biophys Acta 2005;1745(3):287-99
   PubMed Web of Science ®Google Scholar
• Zou JY, Crews FT. TNF alpha potentiates glutamate neurotoxicity by inhibiting glutamate uptake in organotypic brain slice cultures: neuroprotection by NF kappa B inhibition. Brain Res 2005;1034(1-2):11-24
   PubMedGoogle Scholar
• Bezzi P, Domercq M, Brambilla L, CXCR4-activated astrocyte glutamate release via TNFalpha: amplification by microglia triggers neurotoxicity. Nat Neurosci 2001;4(7):702-10
   PubMedGoogle Scholar
• Leonoudakis D, Zhao P, Beattie EC. Rapid tumor necrosis factor alpha-induced exocytosis of glutamate receptor 2-lacking AMPA receptors to extrasynaptic plasma membrane potentiates excitotoxicity. J Neurosci 2008;28(9):2119-30
   PubMedGoogle Scholar
• Tilleux S, Hermans E. Neuroinflammation and regulation of glial glutamate uptake in neurological disorders. J Neurosci Res 2007;85(10):2059-70
   PubMedGoogle Scholar
• Sitcheran R, Gupta P, Fisher PB, Baldwin AS. Positive and negative regulation of EAAT2 by NF-kappaB: a role for N-myc in TNFalpha-controlled repression. EMBO J 2005;24(3):510-20
   PubMedGoogle Scholar
• Ehrlich LC, Hu S, Peterson PK, Chao CC. IL-10 down-regulates human microglial IL-8 by inhibition of NF-kappaB activation. Neuroreport 1998;9(8):1723-6
   PubMedGoogle Scholar
• Chiarugi A. Characterization of the molecular events following impairment of NF-kappaB-driven transcription in neurons. Brain Res Mol Brain Res 2002;109(1-2):179-88
   PubMedGoogle Scholar
• Nurmi A, Lindsberg PJ, Koistinaho M, Nuclear factor-kappaB contributes to infarction after permanent focal ischemia. Stroke 2004;35(4):987-91
   PubMed Web of Science ®Google Scholar
• Sorg O, Horn TF, Yu N, Inhibition of astrocyte glutamate uptake by reactive oxygen species: role of antioxidant enzymes. Mol Med 1997;3(7):431-40
   PubMedGoogle Scholar
• Ginis I, Hallenbeck JM, Liu J, Tumor necrosis factor and reactive oxygen species cooperative cytotoxicity is mediated via inhibition of NF-kappaB. Mol Med 2000;6(12):1028-41
   PubMedGoogle Scholar
• O'Neill LA, Kaltschmidt C. NF-kappa B: a crucial transcription factor for glial and neuronal cell function. Trends Neurosci 1997;20(6):252-8
   PubMedGoogle Scholar
• Pizzi M, Spano P. Distinct roles of diverse nuclear factor-kappaB complexes in neuropathological mechanisms. Eur J Pharmacol 2006;545(1):22-8
   PubMedGoogle Scholar
• Teng FY, Tang BL. NF-kappaB signaling in neurite growth and neuronal survival. Rev Neurosci 2010;21(4):299-313
   PubMedGoogle Scholar
• Fridmacher V, Kaltschmidt B, Goudeau B, Forebrain-specific neuronal inhibition of nuclear factor-kappaB activity leads to loss of neuroprotection. J Neurosci 2003;23(28):9403-8
   PubMed Web of Science ®Google Scholar
• Mattson MP. NF-kappaB in the survival and plasticity of neurons. Neurochem Res 2005;30(6-7):883-93
   PubMed Web of Science ®Google Scholar
• Pizzi M, Sarnico I, Boroni F, NF-kappaB factor c-Rel mediates neuroprotection elicited by mGlu5 receptor agonists against amyloid beta-peptide toxicity. Cell Death Differ 2005;12(7):761-72
   PubMedGoogle Scholar
• Cruise L, Ho LK, Veitch K, Kainate receptors activate NF-kappaB via MAP kinase in striatal neurones. Neuroreport 2000;11(2):395-8
   PubMedGoogle Scholar
• Guerrini L, Blasi F, Denis-Donini S. Synaptic activation of NF-kappa B by glutamate in cerebellar granule neurons in vitro. Proc Natl Acad Sci USA 1995;92(20):9077-81
   PubMedGoogle Scholar
• Tolosa L, Caraballo-Miralles V, Olmos G, Llado J. TNF-alpha potentiates glutamate-induced spinal cord motoneuron death via NF-kappaB. Mol Cell Neurosci 2011;46(1):176-86
   PubMedGoogle Scholar